Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for ENTRESTO
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
- Enhancing the Natriuretic Peptide System in HFpEF
- Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB
- ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
- Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers
- Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
- Sacubitril/Valsartan in Resistant Hypertension
- Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
- NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure
- The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation
- Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study
- Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
- Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
- Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure
- The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans
- Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes
- Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure
- PDD in Type 2 Diabetes w/wo Diastolic Dysfunction
- Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
- The Effects of Neprilysin on Glucagon-like Peptide-1
- 177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer
- Role of ARNi in Ventricular Remodeling in Hypertensive LVH
- Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition
- Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
- Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure
- Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD
- Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction
- Comparing ARNI With ACE Inhibitor on Endothelial Function
- Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
- PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
- Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
- EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
- Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)
- Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart Failure
- Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis
- Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
- Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease
Clinical trials list
click for details